Drug Database
IB

ibrutinib

✓ Approved

Johnson & Johnson Services, Inc. · Companion diagnostic · Companion diagnostic

What is ibrutinib?

ibrutinib is a companion diagnostic developed by Johnson & Johnson Services, Inc.. It is approved for therapeutic indications via others.

Drug Profile

CompanyJohnson & Johnson Services, Inc.
Drug ClassCompanion diagnostic
RouteOthers
StatusApproved
Sources: ClinicalTrials.gov, Johnson & Johnson Services, Inc.

Therapeutic Indications

ibrutinib is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Uterine cancer✓ Approved

Related Research Articles

PubMedbioRxiv : the preprint server for biology2026-07-17

Stereoselective Covalent Targeting of BTK(C481S) and Kinases with β-Lactone Electrophiles.

Wang Celine D CD, Barzova Polina E PE, Robles Julian J, Toriki Ethan S ES et al.

The cysteine to serine mutation at residue 481 of Bruton's tyrosine kinase (BTK) is the most common mechanism of clinical resistance against ibrutinib for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. We report small molecule ligands containing chiral β-lactone electrophiles to address this challenge. The asymmetric warhead enabled stereoselective covalent modification of wild-type and ibrutinib-resistant mutant BTK(C481S) through distinct sites of reactivity. Building on these findings, we developed kinase-directed β-lactone probes and demonstrated that individual enantiomers preferentially engage distinct subsets of the kinome. These studies establish β-lactones as stereochemically encodable covalent warheads whose stereochemistry can serve as a selectivity filter in covalent drug discovery.

PMID 42465337
Read full article →
PubMedAmerican journal of cancer research2026-07-17

Efficacy and safety analysis of a novel BTK inhibitor in patients with mantle cell lymphoma harboring TP53 mutations.

Liu Min M, Ding Yannong Y, Lan Hui H

To rigorously evaluate the efficacy and safety of a novel Bruton tyrosine kinase inhibitor (BTKi), alone or in combination with venetoclax, in patients with TP53-mutated mantle cell lymphoma (MCL), focusing on survival outcomes, depth of response, minimal residual disease (MRD), clearance, and treatment-emergent toxicities. We conducted a retrospective, observational cohort study of consecutive adults with TP53-mutated MCL treated with BTKi-based regimens between January 2022 and December 2025. Patients were assigned to BTKi monotherapy (ibrutinib or acalabrutinib; n = 108) or BTKi plus venetoclax (n = 112). Clinical, pathological, and genomic data were recorded using standardized electronic case-report forms. Responses were assessed according to contemporary MCL criteria, and recurrence/progression-free survival (RFS/PFS) and overall survival (OS) were calculated from predefined time points. Combined treatment significantly prolonged median RFS from 11 to 34 months (HR for recurrence or death 0.42, 95% CI 0.29-0.61; P<0.001), and median OS from 20 to 50 months (HR 0.44, 95% CI 0.31-0.63; P<0.001). Overall response rates were higher with BTKi-based combination therapy (76.8% vs. 58.3%; P = 0.001), with comparable rates of complete response. In multivariable models, BTKi-based combination therapy remained independently associated with longer PFS (HR 0.187, 95% CI 0.079-0.442; P<0.001). In patients with TP53-mutated MCL, BTKi-based combination therapy confers clinically meaningful and durable improvements in RFS and OS, with higher overall response rates than monotherapy and acceptable toxicity profiles.

PMID 42464999
Read full article →
PubMedScientific reports2026-07-17

Characteristics of Staphylococcus lugdunensis isolated from humans and animals.

Prorok Paulina P, Skrok Milena M, Karwańska Magdalena M, Siedlecka Magdalena M et al.

Staphylococcus lugdunensis is an opportunistic coagulase-negative Staphylococcus increasingly reported in both humans and companion animals. In this study, we performed a comprehensive characterization of S. lugdunensis isolates obtained from different hosts and clinical backgrounds. Species identification was conducted using MALDI-TOF MS and confirmed by PCR targeting the species-specific fbl gene, complemented by partial rpoB sequencing. The isolates were analysed using multilocus sequence typing (MLST), PCR-based detection of antimicrobial resistance genes, and phenotypic antimicrobial susceptibility testing. Biofilm formation was assessed using a crystal violet microtiter plate assay under different incubation temperatures, and the virulence of selected strains was evaluated using the Galleria mellonella larvae infection model. The isolates exhibited genetic diversity and variable antimicrobial resistance and biofilm phenotypes. Among the analysed isolates, biofilm production was significantly influenced by incubation temperature and host origin, and selected strains caused differential larval survival in the G. mellonella model. Collectively, these findings highlight the heterogeneity of the analysed S. lugdunensis collection comprising human- and animal-derived isolates and support the need for further studies within the One Health framework.

PMID 42463811
Read full article →
PubMedJournal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy2026-07-17

Mycoplasma Pneumonia Diagnostic Prediction Score: Is it possible to differentiate between Mycoplasma pneumoniae pneumonia and SARS-CoV-2 pneumonia?

Miyashita Naoyuki N, Nakamori Yasushi Y, Ogata Makoto M, Fukuda Naoki N et al.

The Mycoplasma Pneumonia Diagnostic Prediction Score, recommended in pneumonia guidelines, is a useful method for differentiating Mycoplasma pneumoniae pneumonia from bacterial pneumonia. On the other hand, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a common microorganism in community-acquired pneumonia, so we investigated whether the Mycoplasma Score can differentiate between M. pneumoniae pneumonia and SARS-CoV-2 pneumonia. Analysis was performed on 162 patients with M. pneumoniae, 422 patients with the Ancestral strain, 262 with the Alpha variant, 274 with the Delta variant, and 1,241 with the Omicron variant. When using the Mycoplasma Score, the sensitivity for predicting M. pneumoniae pneumonia was 71.8%. The diagnostic specificity was 81.3% for the Ancestral strain, 81.7% for the Alpha variant, 77.4% for the Delta variant, and 88.2% for the Omicron variant. The specificity for all SARS-CoV-2 pneumonia cases was 84.8%. When targeting the currently circulating Omicron variant, the diagnostic specificity ranged from 83.9% to 92.7%, showing differences among subvariants. Differences between the two groups were identified using four parameters: age, underlying disease, severity of cough, and use of rapid diagnostic methods. When comparing M. pneumoniae pneumonia and SARS-CoV-2 pneumonia, the diagnostic sensitivity of the Mycoplasma Pneumonia Diagnostic Prediction Score was 71.8%, and the diagnostic specificity was 84.8%. However, when targeting the currently circulating SARS-CoV-2 Omicron variant pneumonia, the diagnostic specificity increased to 88.2%, suggesting that it is possible to differentiate between M. pneumoniae pneumonia and SARS-CoV-2 pneumonia. However, the specificity is lower than that for differentiating bacterial pneumonia.

PMID 42463011
Read full article →
PubMedCureus2026-07-17

Aggressive B-cell Lymphoma Masquerading as Benign Epstein-Barr Virus (EBV)-Related Splenomegaly: An Analysis of Diagnostic Anchoring Bias.

Savadkar Amrut A, Chauhan Ipsita I, Sharma Mansi M, Rallabandi Suhasini S et al.

We report a case involving a 52-year-old male who was initially diagnosed with Epstein-Barr virus (EBV)-related splenomegaly and subsequently identified as having an aggressive B-cell lymphoproliferative disorder. Despite multiple initial diagnostic tests yielding negative results, persistent clinical suspicion due to the worsening patient's condition warranted further investigation, ultimately establishing the correct diagnosis. This case underscores the diagnostic challenges in distinguishing benign viral-associated splenomegaly from underlying malignant lymphoproliferative disorders and highlights the importance of maintaining clinical vigilance when initial diagnostic findings are discordant with the clinical presentation.

PMID 42465140
Read full article →
PubMedBMC medical education2026-07-17

Enhancing ultrasound training for breast cancer diagnosis: a controlled study of AI-assisted learning.

Wu Shuang S, Wang Weihao W, Wu Jian J, Zhou Hong H et al.

This study aimed to develop and evaluate an AI-assisted teaching platform to enhance diagnostic competency in breast ultrasound. The goal was to assess whether AI integration improves diagnostic accuracy, learning efficiency, and participant satisfaction within a residency training program. We conducted a cohort-based study at our hospital. Twelve junior residents (experimental group) underwent AI-assisted training via a newly implemented platform, while twelve senior residents (control group) completed conventional training. Diagnostic performance was evaluated before and after the one-month intervention using consistent assessments. Participant satisfaction was surveyed across domains including learning engagement, skill development, and confidence. In the experimental group, post-intervention diagnostic scores (90.50 ± 9.82) were significantly higher than pre-intervention diagnostic scores(70.00 ± 17.55, P = 0.003,95%CI[-32.54,-8.46], Cohen's d=-1.44). Survey results indicated high satisfaction: 83.33% strongly agreed the platform facilitated learning, 66.67% reported improved pattern recognition, and 66.67% noted increased engagement in self-learning. A majority also reported gains in clinical reasoning and confidence when facing a real patient. We integrated an AI-assisted platform into ultrasound residency training, creating an educational tool. In this single-center exploratory study, the AI-assisted platform shows potential to improve residents' diagnostic skills for breast ultrasound.

PMID 42464241
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about ibrutinib